Fonginox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fonginox

Property Description
Active Ingredient Itraconazole
Form Oral Capsule, Oral Solution, Tablet
Pharmacological Class Triazole Antifungal Agent (Systemic)
General Purpose Treating systemic fungal and yeast infections
Origin Synthetic Chemical Compound

What Type of Medicine is Fonginox?

Fonginox is a brand name medication whose active component is Itraconazole, chemically classified as a synthetic triazole antifungal agent. The drug is clinically recognized for its use in managing serious systemic mycotic infections, differentiating it from topicals. It functions as a systemic antifungal agent, designed to be absorbed internally to circulate in the bloodstream, enabling it to reach deep-seated fungal infection sites that topical treatments cannot effectively access. As a prescription-only medication, Itraconazole belongs to a newer generation of antifungals that offer broad-spectrum coverage against diverse fungal and yeast pathogens. Its general therapeutic purpose is the elimination of the underlying cause of established fungal disease.


Composition and Available Forms of Fonginox

The active ingredient in Fonginox is Itraconazole, a synthetic compound with the molecular formula C35H38Cl2N8O4. This brand typically provides the medication as a single active ingredient product in several key pharmaceutical preparations to ensure optimized patient dosing. Patients primarily receive Itraconazole via the oral route, most commonly as an oral capsule or an oral solution. Clinical studies have demonstrated that the oral solution form, which often utilizes a specialized cyclodextrin component, offers a reliable way for the body to take up the drug. This formulation detail confirms the manufacturer’s focus on enhancing the bioavailability of the active ingredient, a crucial feature in patient care.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Fonginox?

Possible Side Effects and Safety Information: Fonginox (Itraconazole)

Fonginox (Itraconazole) is associated with several safety considerations, including a Boxed Warning from regulatory authorities regarding potential Congestive Heart Failure (CHF), other cardiac effects, and significant drug interactions.

Serious and Clinically Significant Adverse Reactions

Organ System Serious Adverse Reactions
Cardiovascular Congestive Heart Failure (CHF), decreased left ventricular ejection fraction, and cardiac dysrhythmias. Use is contraindicated in patients with evidence or a history of ventricular dysfunction (e.g., CHF). The risk of CHF may be dose-dependent.
Hepatobiliary Serious hepatotoxicity, including cases of fatal acute liver failure. Treatment should be discontinued if signs of liver dysfunction (e.g., anorexia, abdominal pain, dark urine) occur.
Nervous System Peripheral neuropathy (pain, burning, tingling, numbness), generally associated with long-term use. Transient or permanent hearing loss has also been reported.
Dermatologic Severe allergic reactions, including Stevens-Johnson syndrome, anaphylaxis, and toxic epidermal necrolysis.

Common Adverse Reactions

The most common adverse reactions reported in clinical trials include gastrointestinal disturbances (nausea, diarrhea, abdominal pain, vomiting), headache, and rash. Other common effects include elevated liver enzymes, edema, and dizziness.

Contraindications and Safety Restrictions

  • Drug Interactions: Fonginox is a potent inhibitor of the CYP3A4 enzyme, leading to a high risk of drug-drug interactions. Coadministration with numerous medications is strictly contraindicated due to the potential for severe or life-threatening adverse reactions, such as cardiac rhythm disturbances.
  • Pregnancy: Itraconazole is generally contraindicated in pregnant women for non-life-threatening indications due to teratogenic effects observed in animal studies. Women of childbearing potential must use effective contraception during treatment and for two months after therapy concludes.
  • Renal/Hepatic Impairment: Caution is advised; dose adjustments or close monitoring may be required due to altered drug exposure and metabolism in patients with renal or hepatic impairment (e.g., cirrhosis).

Note: This summary reflects officially documented safety information and is not intended as a substitute for professional clinical advice.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documentation specifies that clinical information on human overdose with itraconazole is limited. High exposure is associated with the risk of severe systemic effects. These include signs of Congestive Heart Failure (such as shortness of breath, peripheral edema, or unusual weakness) and evidence of fatal acute liver failure (manifested by jaundice or dark urine). Indications of peripheral neuropathy may also be a severe outcome requiring urgent action.


Antidote and Management Constraints

Authorities explicitly state that no specific antidote is known for itraconazole poisoning. In the event of an overdose, regulatory guidelines mandate that supportive and symptomatic measures should be initiated. Furthermore, regulatory documentation confirms that itraconazole is not removed by dialysis, which guides procedural steps in the management of high exposure.


When to Seek Immediate Medical Help

Regulator-mandated action requires an individual to seek emergency medical attention or contact a poison control center at once if an overdose is suspected. If severe clinical signs—such as those consistent with heart failure or hepatotoxicity—develop during administration, the medication must be immediately discontinued. Additionally, if liver injury is suspected, official guidance requires that liver function testing be performed.

Therapeutic Uses of Fonginox

What Fonginox Treats: Main Uses and Benefits

Fonginox (Itraconazole) is a systemic antifungal medication primarily applied for managing infections caused by a spectrum of fungal and yeast pathogens. This internal approach is relevant when topical treatments cannot always achieve clearance. The medication is used for serious infections that spread through the body, as well as specific localized conditions.


This medication is generally considered relevant in conditions involving episodic or fluctuating manifestations where symptoms are caused by deep-seated or persistent fungal organisms. Common indications include serious systemic mycotic infections like Blastomycosis, Histoplasmosis, and invasive Aspergillosis, and is also relevant for widespread Onychomycosis (nail fungus) and certain oropharyngeal candidiasis.

Fonginox provides the necessary systemic action to address the pathogen present in deep sites. This key benefit contributes to easing the overall symptom load associated with the infectious disease and helps manage symptoms related to systemic imbalance or chronic tissue discomfort. It is also applied preventatively (prophylaxis) in certain immunocompromised patient groups, helping to prevent the onset of severe opportunistic fungal infections and may assist with maintaining comfort and stability.

Quick Fact: Relief for Persistent Discomfort
This medicine is commonly used to help manage persistent or deep-seated symptoms—such as those associated with systemic illness or severe nail dystrophy—when symptoms create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Itraconazole

Eligibility and Restrictions for Use

Who can and cannot use Fonginox?

The population eligibility for Fonginox (Itraconazole) is strictly defined by regulatory warnings, primarily concerning cardiovascular status, pregnancy, and age.

Classification Population or Condition
Absolute Contraindication Patients with known hypersensitivity to the drug or its components.
Absolute Contraindication Patients with a history or presence of congestive heart failure (CHF) for the treatment of onychomycosis.
Absolute Contraindication Pregnant patients, except for life-threatening systemic fungal infections where the benefit is determined to outweigh the risk.
Conditional/Restricted Use Patients with pre-existing hepatic impairment (liver disease) or active liver disease; treatment must generally not be started unless necessary.
Conditional/Restricted Use Patients with renal impairment (kidney disease); use requires caution due to potentially lower drug exposure.
Not Established/Not Recommended Pediatric patients (children and adolescents), as safety and efficacy have not been established.
Not Recommended Older adults and breastfeeding women, due to limited clinical data and the need for careful risk-benefit assessment.

All women of childbearing potential are required by regulators to use effective contraceptive precautions during therapy and for two months after treatment completion.

What should I know about interactions with other medicines?

Fonginox (itraconazole) is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. It is also a potent inhibitor of this system, which means it can significantly increase the blood concentration of many other medicines that are also broken down by CYP3A4, potentially leading to increased or life-threatening side effects.

️ Contraindicated Combinations (Do Not Take Together)

The combination of Fonginox with certain medicines can lead to serious cardiac rhythm problems (QT prolongation, Torsades de Pointes) or profound sedation and is strictly contraindicated. These include, but are not limited to:

Drug Class Examples Potential Risk
HMG-CoA Reductase Inhibitors Lovastatin, Simvastatin Serious muscle damage (Rhabdomyolysis)
Heart Rhythm Drugs Dofetilide, Quinidine, Disopyramide Severe heart rhythm abnormalities
Sedatives/Anxiety Drugs Midazolam (oral), Triazolam Prolonged or excessive sedation
Ergot Alkaloids Ergotamine, Dihydroergotamine Increased toxicity/reduced blood flow
Certain Anti-Allergy Drugs Astemizole, Terfenadine Severe heart rhythm abnormalities

Other Significant Interactions

  • Anticoagulants (e.g., Warfarin): Fonginox can enhance the blood-thinning effect, requiring close monitoring of your International Normalized Ratio (INR) and dosage adjustment to prevent bleeding.
  • Medicines that Decrease Stomach Acid: Antacids, H2-receptor antagonists (e.g., ranitidine), and Proton Pump Inhibitors (PPIs) (e.g., omeprazole) can decrease the absorption of Fonginox capsules, making the antifungal less effective. Follow specific instructions for separating the doses.
  • CYP3A4 Inducers: Drugs like Rifampicin, Carbamazepine, and Phenytoin can dramatically reduce Fonginox blood levels, leading to treatment failure. This combination should generally be avoided.

Mechanism of Action

Fonginox's mechanism of action involves a targeted biochemical interaction with the fungal cell, operating through two primary domains.

Inhibition of Fungal Enzyme CYP51

This domain covers the drug's initial molecular interaction: the Itraconazole molecule directly binds to and inhibits the fungal enzyme Lanosterol 14alpha-demethylase ( CYP51). The molecule's triazole nitrogen atom coordinates with the enzyme's heme iron, functionally deactivating this biological target. This enzyme blockade initiates the cascade, as CYP51 is a critical enzyme required for the synthesis of the fungal cell's structural sterols.

Destabilization of the Cell Membrane

The inhibition of CYP51 immediately disrupts the Ergosterol Biosynthesis Pathway. This results in a dual physiological consequence: the fungal cell cannot produce ergosterol (its main structural component), and, simultaneously, toxic intermediate sterols accumulate. The combination of structural deficit and toxicity leads to a loss of fungal cell membrane integrity, resulting in fungistatic activity (growth cessation) or fungicidal activity (cell death).

Dosage and Administration Information

Fonginox (Itraconazole) usage is highly dependent on the specific formulation, administration schedule, and clinical context, following strict guidelines to ensure appropriate systemic exposure.

Administration and Scheduling

The primary route is oral via capsules, tablets, or solution. For life-threatening systemic infections, a loading dose of 200 mg (Standard Capsule) three times daily (TID) is required for the initial three days of therapy. For maintenance, the standard dose is 200 mg once daily, with doses over 200 mg needing to be administered in two divided doses.

Specific conditions, such as onychomycosis, often employ pulse dosing, which involves taking 200 mg twice daily for one week, separated by a three-week drug-free interval. Treatment duration is prolonged, ranging from a minimum of 12 weeks for continuous onychomycosis up to 3 to 12 months for systemic mycoses.

Context-of-Use Requirements

Administration conditions are strictly tied to food intake and gastric acidity due to the drug's variable absorption:

Formulation Instruction for Intake
Oral Capsules/Tablets Must be taken immediately after a full meal for optimal absorption.
Oral Solution Must be taken on an empty stomach (refrain from eating for at least 1 hour after intake).

Crucially, the Oral Solution and Capsules are not interchangeable due to differences in bioavailability. If a patient is taking acid-reducing medicines, the capsules may be administered with an acidic beverage (e.g., non-diet cola) to facilitate absorption. Acid-neutralizing medicines must be taken at least two hours after the capsule dose. Dose adjustments may be necessary for patients with hepatic or renal impairment, as explicitly stated in the official labels for these populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action

Research has explored the drug's action. This action was studied to determine whether it is associated with a reduction in pain and inflammation in affected joints. Studies examined the drug when used at the dose specified in the trial protocol.


Key Clinical Findings

Clinical trials examined the drug's effect in adult patients with active Rheumatoid Arthritis (RA).

Efficacy and Symptom Reduction

Overall, the evidence was evaluated to assess outcomes in patients diagnosed with Rheumatoid Arthritis (RA). The primary goal of the research was to evaluate changes in disease activity scores, such as the DAS28 and ACR scores, compared to placebo.

  • Disease Activity: Multiple randomized controlled trials (RCTs) examined whether the drug was associated with reaching a low disease activity state. Research evaluated whether the drug was associated with favorable changes in patients' quality of life scores over 12 weeks in some studies.
  • Symptom Relief: Studies examined the time to onset of effect and whether the drug was associated with changes in symptoms during acute flare-ups.

Comparison to Other Treatments

Combination therapy was compared to standard monotherapy to assess differences in outcomes. Research evaluated whether combining the drug with standard disease-modifying anti-rheumatic drugs (DMARDs) resulted in greater changes to the disease activity index compared to DMARDs alone.


Safety and Tolerability Profile

The safety profile and tolerability were assessed in clinical trials. Studies monitored adverse events, including gastrointestinal issues and infection rates.

  • Subgroup Analysis: Patients with pre-existing kidney conditions were assessed in trials to evaluate the drug's effect on this subgroup.
  • Common Adverse Events: The most frequently observed events in the study population included mild headaches, nausea, and injection site reactions. The duration of these events was also monitored in the studies.

Key Studies & References American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis (Most Recent Update)

Frequently Asked Questions (FAQ)

Common questions about Fonginox (FAQ)


Q: How quickly should I expect to see results after starting Fonginox?

Studies and official product information indicate that while the drug reaches peak blood concentrations within a few hours of an oral dose, it requires about 15 days of repeated dosing to reach its steady-state level in the blood. For treatment of the skin and nails, the drug can persist in these tissues for weeks to months after the course of treatment has been finished.


Q: Does Fonginox interact with common pain relievers like ibuprofen?

Fonginox, which contains itraconazole, is known to be a potent inhibitor of the CYP3 A4 enzyme system, which is responsible for breaking down many other medicines. Regulatory documents state that this can lead to increased concentrations of some co-administered drugs. Patients are generally advised to discuss all pain relievers, including over-the-counter options, with a prescribing healthcare professional to assess potential interactions.


Q: Is it normal to feel a tingling sensation when applying Fonginox?

Official regulatory documents note that peripheral neuropathy has been reported, especially with long-term use. This condition can include symptoms such as tingling, numbness, or pain. If you experience new or worsening neurological symptoms while taking Fonginox, the appearance of new or worsening neurological symptoms warrants consultation with a healthcare professional.


Q: How long does Fonginox remain effective after the expiration date?

According to official product information, Fonginox must be discarded after the expiration date printed on the package. Its chemical stability and effectiveness are only guaranteed up to that date. Disposal should follow proper guidelines, such as local medicine take-back programs, to maintain safety.


Q: Does taking Fonginox make you more sensitive to the sun?

Official postmarketing experience reports have indicated that photosensitivity (increased sensitivity to sunlight) has occurred in some patients using Fonginox. Patients are generally advised to take appropriate precautions regarding sun exposure while using this medication.


Q: What should I do if the area treated with Fonginox looks redder?

Redness and rash are among the commonly reported adverse reactions. However, regulatory warnings note that severe skin reactions, such as blistering or a spreading rash, and signs of liver dysfunction (like dark urine or fever) require immediate attention. If symptoms appear to worsen or new severe symptoms occur, discontinuation of treatment should be discussed with a healthcare professional, as should the development of any severe symptoms.


Q: Is Fonginox known to interact with blood pressure medication?

Yes. Official drug interaction information highlights that Fonginox can interact with certain types of blood pressure medications, specifically some calcium channel blockers. Since Fonginox inhibits the enzyme that metabolizes these drugs, combining them can lead to elevated blood concentrations of the blood pressure medicine, potentially causing serious effects like excessive hypotension (low blood pressure) or fluid retention.


Q: Does alcohol consumption affect how Fonginox works in the body?

Official patient information indicates that patients are generally advised to avoid consuming alcohol while taking Fonginox. This precaution is recommended because alcohol consumption can potentially increase the risk of certain side effects, particularly those involving the liver.


Q: Is it possible to be allergic to an ingredient in Fonginox?

Yes, it is possible. Regulatory documents clearly state that Fonginox is contraindicated (should not be used) in any patient who has a known hypersensitivity (allergic reaction) to itraconazole or any of the inactive components of the formulation.


Q: What are the long-term safety concerns of using Fonginox?

Regulatory warnings highlight serious potential risks, including Congestive Heart Failure and Hepatotoxicity (liver damage), which are risks that typically require medical monitoring, especially when the drug is used long-term. Additionally, peripheral neuropathy (nerve damage) has been reported in patients undergoing extended therapy with this medication.


Q: Why is Fonginox sometimes mentioned as having anti-inflammatory properties?

While the drug's established primary function is antifungal, official research summaries mention that clinical studies have been conducted to examine if the drug's mechanism is also associated with a reduction in pain and inflammation in affected joints.


Q: Is there a maximum time someone can use Fonginox safely?

The required treatment duration for Fonginox varies widely based on the specific infection being treated, ranging from a few weeks up to 12 months for systemic mycoses. Official product information notes that safety data for continuous use beyond six months are limited for certain formulations. Extended therapy may require careful monitoring by a healthcare provider due to the limited data.


Q: Is Fonginox suitable for people who have had organ transplants?

Official regulatory warnings note that Fonginox should be used with extreme caution in patients who have received an organ transplant. This is because Fonginox is a strong inhibitor of the enzyme that breaks down many immunosuppressant drugs used by transplant patients, which can dangerously increase their concentration in the body. Furthermore, absorption of Fonginox may be reduced in these patients.


Q: How does Fonginox prevent the infection from returning?

The primary regulatory guidance focuses on the importance of treatment duration. Official prescribing information indicates that an inadequate period of treatment may lead to the recurrence of active infection. By completing the full, prescribed course, the medicine ensures the fungus is fully eliminated, which is the key mechanism to prevent its return.


Q: How long after stopping Fonginox can I try another treatment?

Fonginox is known to persist in the body's tissues for a long time. It is eliminated from the plasma (blood) within about 7 to 14 days, but it can remain in places like nail keratin for at least six months. Due to this persistence and the high risk of drug interactions, consultation with a healthcare professional is recommended before starting any new medication after stopping Fonginox.

How should Fonginox be stored and disposed of?

Storage and Disposal Requirements

Fonginox (Itraconazole) must be stored strictly according to official regulatory specifications. The requirements vary by formulation:

Formulation Required Storage Condition
Oral Capsules Store at controlled room temperature, between 15°C and 25°C (59°F and 77°F). Must be kept in the original, tightly closed container and protected from light and moisture.
Oral Solution Store at or below 25°C (77°F). The solution must not be frozen.

All forms of this medication must be kept out of the sight and reach of children.

Unused or expired Fonginox must be properly disposed of by following local regulatory requirements or utilizing official medicine take-back programs. The medicine should not be disposed of down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fonginox found in:

A-Z Index: